# China NMPA Product Recall - Isatis root granules (sugar-free, with sugar) and Wuling capsules

Source: https://www.globalkeysolutions.net/records/china_product_recall/jiangxi-pinxin-pharmaceutical-co-ltd/f87e3229-8568-46ab-aebf-829b16222217
Source feed: China

> China NMPA product recall for Isatis root granules (sugar-free, with sugar) and Wuling capsules by Jiangxi Pinxin Pharmaceutical Co., Ltd. published November 02, 2018. Recall level: . The National Medical Products Administration (NMPA) issued a notice on November 2, 2018, requesting 

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: Notice Regarding Assistance in the Recall of Problematic Products from Jiangxi Pinxin Pharmaceutical Co., Ltd.
- Company Name: Jiangxi Pinxin Pharmaceutical Co., Ltd.
- Publication Date: 2018-11-02
- Product Name: Isatis root granules (sugar-free, with sugar) and Wuling capsules
- Discovering Company: Xinyu City Market and Quality Supervision Administration, Jiangxi Province
- Manufacturing Company: Jiangxi Pinxin Pharmaceutical Co., Ltd.
- Summary: The National Medical Products Administration (NMPA) issued a notice on November 2, 2018, requesting assistance in recalling problematic pharmaceutical products from Jiangxi Pinxin Pharmaceutical Co., Ltd. The affected products include Banlangen Granules (both sugar-free and sugar-containing) and Wuling Capsules, specifically those produced up to November 2016. While the specific nature of the problems is not detailed, the recall indicates identified quality or safety concerns with these medications. The regulatory framework involves coordination between the NMPA, the Market and Quality Supervision Administration of Xinyu City, Jiangxi Province, and various regional Food and Drug Administrations, including those in Ili Kazakh Autonomous Prefecture, Urumqi, and Karamay within the Xinjiang Uygur Autonomous Region. Required actions include notifying distributors such as Xinjiang Lisheng Pharmaceutical Co., Ltd. and Sinopharm Xinjiang Xinte Pharmaceutical Co., Ltd., to promptly conduct the drug recall. Additionally, regional administrations are mandated to intensify supervision and inspection efforts to ensure the comprehensive retrieval of all problematic drugs. A written report detailing the recall progress must be submitted to the Drug and Cosmetics Market Supervision Division of the Xinjiang Uygur Autonomous Region Food and Drug Administration by December 15th, 2018, emphasizing accountability and public safety.

Company: https://www.globalkeysolutions.net/companies/jiangxi-pinxin-pharmaceutical-co-ltd/bdb1ef72-0c91-401f-9c5b-1a9deab9a631